|Abiomed Climbs to Record After Fiscal Q4 EPS, Rervenue Beat Analyst Estimates 12:26 PM ET, 05/03/2018 - MT Newswires12:26 PM EDT, 05/03/2018 (MT Newswires) -- Abiomed (ABMD) shares rose 11% to a record after reporting fiscal Q4 EPS of $0.80 compared with $0.33 a year earlier, beating the $0.66 average estimate of analysts in a Capital IQ poll. |
The new 52-week range is $123.60 to $338.69.
Revenue was $174.4 million, an increase of 40% from $124.7 million a year earlier. That exceeded the $164.3 million analyst consensus.
The company sees total revenue in the 2019 fiscal year to be in the range of $740 million to $770 million, an increase of 25% to 30% over the previous fiscal year. It sees GAAP operating margin in the range of 28% to 30%.
Closing price: 358.16 Change +10.78 (+3.1%)